(0.20%) 5 141.75 points
(0.19%) 38 513 points
(0.27%) 17 893 points
(-0.92%) $83.08
(1.56%) $1.953
(-0.16%) $2 343.40
(0.87%) $27.49
(0.26%) $924.50
(-0.18%) $0.933
(-0.18%) $11.01
(-0.26%) $0.798
(1.08%) $92.87
2.08% HKD 34.30
Live Chart Being Loaded With Signals
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments...
Stats | |
---|---|
Dagens volum | 3.13M |
Gjennomsnittsvolum | 2.59M |
Markedsverdi | 44.42B |
EPS | HKD0.562 ( 2023-09-30 ) |
Last Dividend | HKD0.616 ( 2023-05-25 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 13.56 |
ATR14 | HKD0.104 (0.30%) |
Volum Korrelasjon
Hangzhou Tigermed Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Hangzhou Tigermed Korrelasjon - Valuta/Råvare
Hangzhou Tigermed Økonomi
Annual | 2023 |
Omsetning: | HKD7.38B |
Bruttogevinst: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2023 |
Omsetning: | HKD7.38B |
Bruttogevinst: | HKD2.85B (38.58 %) |
EPS: | HKD2.34 |
FY | 2022 |
Omsetning: | HKD7.09B |
Bruttogevinst: | HKD2.81B (39.64 %) |
EPS: | HKD2.32 |
FY | 2021 |
Omsetning: | HKD5.21B |
Bruttogevinst: | HKD2.27B (43.55 %) |
EPS: | HKD3.31 |
Financial Reports:
No articles found.
Hangzhou Tigermed Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.616 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.362 | 2021-05-25 |
Last Dividend | HKD0.616 | 2023-05-25 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD1.557 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.54 | -- |
Div. Sustainability Score | 8.20 | |
Div.Growth Potential Score | 5.20 | |
Div. Directional Score | 6.70 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2289.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1277.HK | Ex Dividend Knight | 2023-10-09 | Semi-Annually | 0 | 0.00% | |
0335.HK | Ex Dividend Knight | 2023-09-04 | Annually | 0 | 0.00% | |
6069.HK | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
1836.HK | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
0861.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0012.HK | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
2611.HK | Ex Dividend Junior | 2023-06-09 | Annually | 0 | 0.00% | |
1402.HK | Ex Dividend Junior | 2023-08-10 | Sporadic | 0 | 0.00% | |
0480.HK | Ex Dividend Knight | 2023-08-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.274 | 1.500 | 4.52 | 6.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.0682 | 1.200 | 7.73 | 9.27 | [0 - 0.3] |
returnOnEquityTTM | 0.0978 | 1.500 | -0.0245 | -0.0367 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 2.74 | 0.800 | 1.295 | 1.036 | [1 - 3] |
quickRatioTTM | 2.71 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.793 | 1.500 | 1.151 | 1.727 | [0.2 - 2] |
debtRatioTTM | 0.114 | -1.500 | 8.10 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8 465.38 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.161 | -1.500 | 9.35 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.386 | 1.000 | 6.90 | 6.90 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.337 | 1.000 | 5.26 | 5.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.499 | 1.000 | 8.34 | 8.34 | [0.2 - 2] |
assetTurnoverTTM | 0.249 | 0.800 | -1.675 | -1.340 | [0.5 - 2] |
Total Score | 8.20 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.02 | 1.000 | 8.69 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0978 | 2.50 | -0.0157 | -0.0367 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.589 | 2.00 | 9.47 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.879 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.951 | 2.00 | 9.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | 0.160 | 1.500 | -2.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.229 | 1.000 | 6.78 | 0 | [0.1 - 0.5] |
Total Score | 5.20 |
Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.